Drugs / 2013 A/H7N9 IIV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03589807 | Aug 2018 → Jun 2020 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2013 A/H7N9 IIV | “3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1” NCT03589807 ↗ |
| Modality | Vaccine | “Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from...” NCT03589807 ↗ |
| Route | Intramuscular | “2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly” NCT03589807 ↗ |